It sits between tirzepatide (around 14.9% in SURMOUNT-1) and semaglutide (around 6.9% in STEP-1)
That enrolment breakdown is worth stating carefully, because the trials own abstract phrases it in a way that is easy to misread: it says 706 participants were assigned to cagrilintide 0.34.5 mg (100102 per dose group), 99 to liraglutide 3.0 mg, and 101 to placebo. Read literally, that would put the trial at over 900 people
Some individuals may experience mild injection site reactions, temporary fatigue, or slight headache
Images were collected using a CFI Plan Apochromat Lambda D oil immersion objective (60, NA = 1.4) and for roGFP imaging a CFI Plan Apo VC water immersion objective (60, NA = 1.2)
Supporting Enzymes and Hormones : Proteins make up many enzymes and hormones, which help with processes like digestion and hormone regulation
What is Semaglutide Peptide Mapping